All of the relevant financial relationships listed for these individuals have been mitigated. Unless otherwise noted, speakers have nothing to disclose.

Moderators

Norihisa Shigemura, MD
Michael Mulligan, MD

Presentations

1. Who to Transplant: Indication for Transplant, COPD, IPF, CF, Scleroderma, Sarcoidosis
   Shaf Keshavjee, MD MSc FRCSC FACS
   Disclosure(s): Abbott: Advisory Board (Ongoing); CareDx: Advisory Board (Ongoing); CSL Behring: Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing); Lung Bioengineering: Consultant (Ongoing); SQI Diagnostics: Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Terminated, October 22, 2023); Traferox Technologies: Ownership Interest (stocks, stock options, patent or other intellectual property or other ownership interest excluding diversified mutual funds) (Ongoing); United Therapeutics: Consultant (Ongoing), Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing)
    
2. Who Not to Transplant, Deconditioning/Reconditioning
   Matthew Hartwig, MD
   Disclosure(s): Biomedinnovations: Consultant (Ongoing); CSL Behring: Advisory Board (Ongoing); Paragonix: Consultant (Terminated, October 16, 2023); Transmedics Inc: Advisory Board (Ongoing), Ownership Interest (stocks, stock options, patent or other intellectual property or other ownership interest excluding diversified mutual funds) (Ongoing)
    
3. ECMO as Bridge to Lung Transplant
   Jasleen Kukreja, MD
   Disclosure(s): Guidepoint Consulting: Consultant (Ongoing); Lung Bioengineering: Advisory Board (Terminated, August 31, 2023)
    
4. Single vs Double, Lung vs Heart-Lung Transplant
   John MacArthur Jr., MD
    
5. Unusual Challenges in Candidate Selection—Metastatic Cancers, Highly Sensitized Patients
   Ankit Bharat, MBBS
    
6. Panel Discussion